These mechanistic disparities underscore the importance of tumor context in determining the biological and clinical impact of PIEZO2 and suggest that therapeutic strategies should be tailored to its expression and epigenetic status in each malignancy. The gene discussed is PIEZO2; the disease is neoplasm.